Crinetics Pharmaceuticals(CRNX)
SAN DIEGO, CAPharmaceutical
Focus: Crinetics is a public, clinical-stage biopharmaceutical company focused on small-molecule therapeutics for neuroendocrine and endocrine disorders. The company operates as a specialized player in rare disease markets with a concentrated pipeline in somatostatin and melanocortin receptor agonism.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
36-7 this month
Cooling — net -7 jobs in 30d
5 added, 12 removed. Slower than typical.
Should You Work at Crinetics Pharmaceuticals?
AI assessmentBest suited for early-stage career scientists and clinical operations professionals willing to accept financial risk for meaningful rare disease impact and upside participation.
Why Work Here
- Early commercial milestone: PALSONIFY (paltusotine) launched in 2024 for acromegaly, transitioning company from pure R&D to revenue-generating stage
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$4M
Key Products
Growing
Growth17.9yr
First FDA-approved oral somatostatin receptor 2 agonist for acromegaly with selective SSTR2 activity (>4000-fold), launched in 2024 and currently the company's only marketed product.
Help build intelligence for Crinetics Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.